Linker technology in antibody-drug conjugates for cancer treatment

Abstract

Linker technology is important for antibody-drug conjugate development. Linker connects antibody and anti-cancer agent. The linkage between antibody-drug conjugate must be stable during blood circulation, yet the anti-cancer agent should be released at cancer lesion. In this manuscript, the aspect of various linkers and spacers will be described.